SICHUAN EXPRESS (00107) announced its interim results, with a net profit attributable to shareholders of 901 million yuan, an increase of 1.96% year-on-year.

20:32 27/08/2026

Sichuan Chengyu Expressway (00107) announced its interim results for the six months ending June 30, 2026, with group revenue of RMB 4.887 billion, a year-on-year increase of 12.55%; profit attributable to shareholders of RMB 901 million, a year-on-year increase of 1.96%; and earnings per share of RMB 0.28.

SICHUAN EXPRESS (00107) announced its interim results for the six months ending June 30, 2026, with a group revenue of RMB 4.887 billion, an increase of 12.55% year-on-year; the profit attributable to shareholders was RMB 901 million, an increase of 1.96% year-on-year; earnings per share were RMB 0.28.

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.

TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).